A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 55
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : PC-RPLND
Long Form : postchemotherapy retroperitoneal lymph node dissection
No. Year Title Co-occurring Abbreviation
2020 Clinical outcome of post-chemotherapy retroperitoneal lymph nodedissection in metastatic nonseminomatous germ cell tumour: Asystematic review. MI-RPLND, NSGCT, O-RPLND
2020 Post-chemotherapy retroperitoneal lymph node dissection for non-seminomatous germ cell tumors: A single-surgeon, Canadian experience. NSGCT, PCRM
2020 Prognostic Value of Teratoma in Primary Tumor and Postchemotherapy Retroperitoneal Lymph Node Dissection Specimens in Patients With Metastatic Germ Cell Tumor. GCT, NSGCT, ORCH, OS, PFS
2019 Management of residual masses in testicular germ cell tumors. ---
2019 Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group. NSGCT
2018 Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. EC
2018 Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. CI, GCT
2018 Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes. NCDB, NSGCTs, OS, PSM
2018 Preservation of Ejaculatory Function After Postchemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND) in Patients With Testicular Cancer: Template vs. Bilateral Resection. ---
10  2018 Risk of Bleomycin-Related Pulmonary Toxicities and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Good-Risk Germ Cell Tumors. GCTs, IGCCCG
11  2018 Surgical management and outcomes of patients with bone metastases in germ cell tumors: A case series. BR
12  2017 Management of Duodenal Involvement During Retroperitoneal Lymph Node Dissection for Germ Cell Tumors. ---
13  2017 Modified retroperitoneal lymph node dissection for post-chemotherapy residual tumour: a long-term update. NSGCT
14  2017 [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis]. LDH
15  2016 Characterizing the Morbidity of Postchemotherapy Retroperitoneal Lymph Node Dissection for Testis Cancer in a National Cohort of Privately Insured Patients. ---
16  2016 Is percent seminoma associated with intraoperative morbidity during post-chemotherapy RPLND? GCT, LN, SEM
17  2016 Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients. IQR
18  2016 Post-chemotherapy retroperitoneal lymph node dissection in the management of metastatic testis cancer: the 16-year experience in an Irish setting. ---
19  2016 Sexual dysfunction in testicular cancer patients subjected to post-chemotherapy retroperitoneal lymph node dissection: a focus beyond ejaculation disorders. IIEF
20  2015 Contemporary trends in postchemotherapy retroperitoneal lymph node dissection: Additional procedures and perioperative complications. RP
21  2015 False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma. FDG-PET, FP, SUVs
22  2015 Outcomes of postchemotherapy retroperitoneal lymph node dissection following high-dose chemotherapy with stem cell transplantation. HDCT, OS, RP
23  2015 Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Testicular Cancer: A Single Center Experiences. ---
24  2015 Role of surgical resection for refractory germ cell tumors. ---
25  2015 [Reduced morbidity in resection of residual tumors after chemotherapy for seminoma]. NSGCT
26  2014 A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor. DFCI, NSGCT
27  2014 Beyond stage I germ cell tumors: current status regarding treatment and long-term toxicities. BEP, GCT, NSGCT
28  2014 Predictors of viable germ cell tumor in postchemotherapeutic residual retroperitoneal masses. GCT
29  2014 Surgical removal of retroperitoneal tumors after chemotherapy treated testicular tumors. PET
30  2012 Adjuvant surgery in testicular cancer patients undergoing postchemotherapy retroperitoneal lymph node dissection. GCT
31  2012 Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. ERP, NSGCT, RP
32  2012 Contemporary management of postchemotherapy testis cancer. GCTs, PET
33  2012 Outcomes of the management of post-chemotherapy retroperitoneal lymph node dissection-associated anejaculation. EEJ, FOE, PC, RPLND, TESE
34  2012 Predicting necrosis in residual mass analysis after retroperitoneal lymph node dissection: a retrospective study. GCT
35  2012 Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice. AS, NSGCTs, nsRPLND, PET, TGCTs
36  2011 Role of postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors. GCTs
37  2010 Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? CR, NSGCT, RFS
38  2010 The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. ---
39  2009 Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. AFP
40  2009 Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors. ---
41  2009 Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. NSGCT
42  2009 Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. ---
43  2009 Vena caval reconstruction during postchemotherapy retroperitoneal lymph node dissection for metastatic germ cell tumor. IVC
44  2009 [Stage-specific treatment for testicular germ cell tumours]. GCT, RT
45  2008 Delayed orchiectomy at postchemotherapy retroperitoneal lymph node dissection due to laterality of retroperitoneal metastatic pattern consistent with testicular primary: assessment of pathologic findings. EGCTs
46  2008 Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis. TGCT
47  2007 Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. NSGCT, OR
48  2007 Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. IGCCCG, NSGCT
49  2007 Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. hCG, IGCCC
50  2007 Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? AFP, DSS, IGCCC
51  2006 Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? AFP, IGCCC, NSGCT
52  2005 Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. AFP, beta-hCG, RPLND
53  2004 Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. ---
54  1998 Integration of surgery and systemic therapy: results and principles of integration. ---
55  1997 Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. ---